- The prevalence of obesity has tripled over the past 40yrs, with greater increases in ‘developing’ compared to ‘developed’ countries
- The UK has the sixth highest prevalence for obesity; 64% of adults are overweight or obese
- Only five European countries have a prevalence of obesity of <20%, although the prevalence of overweight adults in these countries is still >50%
- In the USA, 36% are obese and 89% overweight, with similar rates in Canada, Australia and New Zealand
Obesity
Obesity
There are a smorgasbord of relevant curriculum items, including those pertaining to physiological changes and modifications to anaesthetic conduct.
In a CRQ on obesity in 2020 (46% pass rate), candidates fell down on knowing relevant basic science, drug dosing in obesity and physiological effects on the respiratory system.
Another CRQ from 2023 (73% pass rate) was overall "well answered" although specific components on obesity-related hypoventilation syndrome and TIVA dosing were not.
The topic appeared again as a CRQ in 2025 where the definition of lean body weight and pharmacological principles in obesity were poorly answered.
Resources
- Anaesthesia for the obese patient (BJA Education, 2020)
- Pharmacokinetics of anaesthetic drugs at extremes of body weight (BJA Education, 2018)
- Acute pain management in patients with severe obesity (BJA Education, 2024)
- Positive end-expiratory pressure optimisation during general anaesthesia in patients with obesity (British Journal of Anaesthesia, 2026)
- Anaesthesia for Patients Living with Obesity (SOBA Single-Sheet Guidance, 2022)
- Peri-operative management of the obese surgical patient (AAGBI & SOBA Guideline, 2015)
- Obesity & Anaesthesia (WFSA, 2007)
- BMI is commonly used as a measure of obesity
- It is easy to calculate and can aid in planning and preparation
- It does not describe important pathophysiological factors influencing perioperative risk such as body composition, the distribution of tissue (muscle vs. adipose) or the metabolic state
- Class 3 obesity is now termed 'severe obesity', replacing the older term 'morbid obesity'
| Category | BMI (kg/m2) |
| Underweight | <18.5 |
| Normal weight | 18.5 - 24.9 |
| Overweight | ≥25 |
| (Pre-obese | 25 - 29.9) |
| Obese | ≥30 |
| Class 1 obesity | 30 - 34.9 |
| Class 2 obesity | 35 - 39.9 |
| Class 3 (severe) obesity | ≥40 |
- Patients who are overweight or obese can be ASA 1, although class 2 obesity (ASA 2) and class 3 obesity (ASA 3) generate a higher risk
Body composition
- Normally total body weight is comprised of 80% lean body mass (also known as fat-free mass) and 20% fat weight
- In the overweight individual, lean body weight increases slowly relative to the increase in fat weight, so the ratio of total body weight to lean body weight increases
- There is also an increase in total body water
Different weights used for drug dosing
- Total body weight (TBW)
- Ideal body weight (IBW)
- I.e. what the patient should weigh if they had a normal ratio of lean mass to fat
- Calculated using the Broca formula: height in centimetres minus 100 (man) or 105 (woman)
- Lean body weight (LBW)
- The weight of everything except body fat
- Exceeds ideal body weight
- Various calculations exist including the Janmahasatian formula
- Plateaus at 100kg in men and 70kg in women
- As IBW and LBW are calculated using height and sex, they may be the same for obese and non-obese individuals of the same height and gender
- Giving obese patients highly lipid soluble drugs using IBW- or LBW-based dosing may result in lower plasma concentrations than anticipated
- Equally, giving poorly lipid soluble drugs according to IBW or LBW may result in lower plasma concentrations as they do not account for the excess fat mass
- Adjusted body weight (ABW)
- Acknowledges that obese individuals have increased lean body mass and an increased volume of distribution for drugs
- Uses ideal body weight + a correction factor multiplied by the excess between ideal and total body weight
- I.e. ABW = IBW + C(TBW - IBW)
- The use of a drug-specific correction factor reflects differing drug solubility
- Sometimes the ABW40 is used, where the correction factor is set at 40% (a.k.a Servin's formula), for calculating ABW for the purposes of propofol infusions
Respiratory
- Increased risk of difficult facemask ventilation and intubation
- Lung volumes
- Reduced FRC, which falls exponentially with BMI (approximately 5-15% for every 5kg/m2 increase)
- Driven by cephalad displacement of the diaphragm by abdominal fat, plus thoracic and pericardial fat
- The fall in FRC is mainly due to reduced expiratory reserve volume; residual volume is preserved and TLC only mildly reduced
- Worse with central adiposity and when supine
- Closing capacity may encroach on FRC, making patients prone to hypoxia due to shunt
- Respiratory mechanics
- Reduced lung compliance due to increased pulmonary blood volume, altered surfactant function and the weight of mediastinal fat
- Chest wall: the pressure-volume curve shifts to the right; rather than simply reducing compliance, the extra mass imposes an inspiratory threshold load which must be overcome before inflation begins
- Increased airway resistance (inversely related to lung volume)
- Increased O2 consumption & CO2 production
- Overall → increased work of breathing
- Pleural and transpulmonary pressures
- Pleural pressure is normally -5 to +5cmH2O; in obesity it can exceed 15cmH2O supine and reach 30cmH2O under general anaesthesia
- Transpulmonary pressure (airway minus pleural pressure) therefore falls and may become negative at end-expiration, causing airway closure and alveolar collapse in dependent lung regions
- Gas exchange
- V/Q mismatch, as the collapsing dependent lung is also the best perfused
- At BMI >40kg/m2, PaO2 may be reduced by up to 20% and the A-a gradient may be up to four times normal
- PaCO2 is usually normal at rest (unless OHS), but there is limited capacity to meet increased ventilatory demand
- Increased incidence/risk of:
- Sleep disordered breathing (OSA, OHS, non-obstructive hypoxia)
- Asthma
- Chronic inflammatory state caused by excess adipose tissue
- Compression of small airways due to increasing fat deposition within and around the chest & abdomen
- Reversibility not always seen with β2 agonists
- Weight loss improves symptoms
- Pulmonary hypertension
Cardiovascular
- Increased overall blood volume but lower blood volume-per-body weight i.e. 50ml/kg rather than 70ml/kg
- Increased cardiac output
- Reduced venous compliance and increased stressed blood volume, which help maintain venous return despite raised intrathoracic pressure
- Raised cardiac filling pressures, particularly with coexisting diastolic dysfunction
- Structural changes: ventricular hypertrophy, diastolic dysfunction and atrial fibrillation; visceral obesity is a major risk factor for heart failure with preserved ejection fraction
- Increased risk of peri-operative bleeding/blood-loss
| Increased risk of cardiovascular comorbidities |
| Hypertension (10x) |
| Ischaemic heart disease |
| Heart failure |
| Arrhythmias |
| Peripheral vascular disease |
| Venous thromboembolism |
Gastrointestinal & metabolic
- Increased incidence of:
- Insulin resistance ± T2DM
- Hiatus hernia
- GORD
- NASH/Fatty liver/cirrhosis
- Hypercholesterolaemia
- Osteoarthritis
- Metabolic syndrome (3 or more from):
- Central obesity
- Hypertension
- Impaired glucose handling or outright diabetes
- Raised triglycerides
- Reduced HDL cholesterol
- Raised intra-abdominal pressure increases risk of abdominal compartment syndrome
| Physiological variable | Pharmacokinetic consequences |
| ↑ Total body water | ↑ VD |
| ↑ Fat mass | ↑ VD |
| ↑ Plasma protein levels | ↑ Protein binding |
| ↑ Lean body weight | ↑ Clearance (and because CO is ↑) |
Absorption
- Largely unchanged due to preserved gastrointestinal function
- Increased cardiac output, body surface area and gut blood flow do not manifest as clinically significant
- The exception is after bariatric surgery, which can markedly alter oral absorption (see Analgesia in severe obesity)
Distribution
- Increased volume of distribution for both hydrophilic and lipophilic drugs due to increases in both total body water and fat mass
- Increased protein binding due to higher levels of plasma proteins; may reduce free drug fraction
Metabolism
- Cardiac output is higher, as is hepatic and renal blood flow, so drug delivery to organs of metabolism is increased
- This increases clearance and metabolism of flow-limited drugs with a high extraction ratio e.g. propofol, ketamine and morphine
- There is increased Phase II metabolism, which can reduce the clinical effectiveness of drugs cleared by this route e.g. lorazepam
- CYP2E1 activity is increased, which increases production of the hepatotoxic paracetamol metabolite
- Conversely metabolic pathways may be hindered by coalescing comorbidities such as fatty liver disease, chronic kidney disease, smoking or the effects of therapeutic drugs
- Obesity in-and-of itself does not cause consistent effects on hepatic metabolism
Elimination
- Increased cardiac output increases GFR and therefore renal clearance
- Clearance correlates with lean body weight and therefore is increased as LBW increases in obesity
- Methods for calculating clearance may be inaccurate and over/under-estimated
Propofol
- Use LBW for induction boluses as this correlates well with cardiac output (onset) and plasma clearance (offset)
- For TCI, neither the Marsh nor Schnider models are validated at extremes of weight
- Indeed, both become inaccurate at a BMI of >37 (females) or >42 (males)
- Overall require careful monitoring and titration to ensure adequate anaesthesia without overdosing
- Marsh
- Scales doses linearly with total body weight and may cause over-dosing if TBW used in obese patients
- Does scale the central compartment according to weight
- The algorithm does not correct body weight so one should input a calculated LBW
- Preferable to use Servin's formula (ABW40) for propofol infusion using Marsh model
- Benefits from a higher dose to reflect distribution of lipophilic propofol into excess fatty tissue, but may cause exaggerated cardiovascular effects
- Schnider
- May be more suitable as it uses age, height, weight and sex to derive compartment sizes and calculates an individualised ke0
- Does, however, use a fixed central compartment size
- The internal algorithm calculates LBW from TBW using the James formula, so should input the TBW
Thiopentone
- Use IBW for induction dose due to increased VD and longer elimination half-life
Fentanyl
- Rapid onset
- Rapid offset in obesity due to high VD, rapid redistribution (highly lipid soluble) and increased clearance
- However, can accumulate significantly when infused due to high lipid solubility and VD, resulting in prolonged elimination half-life and clinical effect
- Similar effect seen in alfentanil although the prolonged effect is more related to low clearance
- For both fentanyl and alfentanil, LBW dosing is recommended
Remifentanil
- Dosing by TBW can produce cardiovascular depression so dosing should use LBW
- Minto model
- Not validated in obesity
- Uses weight, height and age to calculate a LBW
- Cautious titration is required
Morphine & friends
- Obese patients are at risk of opioid-related respiratory depression due to existing OSA and accumulation of morphine + active metabolites
- Dose by LBW with cautious titration and monitoring
- Codeine and tramadol can pose similar risks due to idiosyncratic metabolism (codeine) and active metabolites (tramadol)
NMBA
- Suxamethonium: dosing by TBW is appropriate as it accounts for increased pseudocholinesterase activity
- Non-depolarising agents
- As they are small polar molecules with a small VD, rate of clearance is largely related to metabolism
- As metabolism correlates with LBW, this should be used for dosing
- Use of TBW leads to prolonged action
- Reversal agents
- Little data exists for sugammadex and evidence supports the use of IBW, ABW40 or TBW, although SOBA guidance suggests using ABW
- Use ABW for neostigmine
Local Anaesthetics
- Dosing by LBW or IBW is recommended
- However, increased plasma protein levels may reduce free fraction of LA and therefore increase dose requirements
- Central neuraxial techniques may be unpredictable because of the effects of obesity on the epidural space
Volatile agents
- Decreased pulmonary uptake due to reduced FRC is offset by the increase in cardiac output
- The peripheral compartment is poorly vascularised somewhat mitigating its increased size
- More lipid-soluble agents may accumulate for prolonged procedures, but for short procedures there is little difference
- Pharmacokinetics of sevoflurane and desflurane unaltered
- The leading causes of perioperative morbidity and mortality in severe obesity are VTE, lower respiratory tract infection and respiratory failure
- Good analgesia facilitates early mobilisation, oral intake and discharge, reducing all of these
- Sleep-disordered breathing is the most important comorbidity for pain management
- Patients with untreated or undiagnosed moderate-to-severe OSA are at greatest risk of postoperative respiratory adverse events, especially with opioid-centric analgesia
- Opioids impair the arousal response, worsen airway obstruction and reduce respiratory rate and effort in a dose-dependent manner
- OSA may also increase pain perception and opioid sensitivity
- The first 24h after a long-acting opioid dose appears to be the most dangerous period
- Other relevant comorbidities: hepatic and renal dysfunction, gastroparesis, chronic pain (osteoarthritis, back pain, fibromyalgia) and psychosocial factors
Principles
- Aim for opioid-sparing rather than opioid-free analgesia; opioid-free anaesthesia may be less effective than hoped and its cardiovascular depressant effects may outweigh the benefits
- Tailor the regimen to the surgery, the patient's comorbidities and the character of their pain
- Regular paracetamol and NSAIDs unless contraindicated
- Prioritise regional and neuraxial techniques where appropriate
- Add antihyperalgesics (ketamine, lidocaine or dexmedetomidine) in high-risk patients, hyperalgesia or neuropathic pain
- A naloxone rescue protocol should be readily available
Paracetamol
- Pre-emptive and regular IV dosing is recommended where possible
- Plasma concentrations are lower in obesity, but the standard 1g (4g/day) dose should not be exceeded because increased CYP2E1 activity produces more hepatotoxic metabolite
- Reduce the dose if there are risk factors for hepatotoxicity e.g. NASH
NSAIDs
- Reduce opioid consumption and recovery room stay after bariatric surgery without increasing surgical complications
- After previous bariatric surgery, short-term use is acceptable but prolonged use is contraindicated due to risk of marginal (anastomotic) ulceration
Dexmedetomidine
- α2-agonist; only licensed for ICU sedation in the UK but widely used intra-operatively in bariatric practice
- In its clinical range it does not depress airway tone or respiratory drive, so is particularly useful in OSA
- Excessive doses cause prolonged sedation, hypotension and bradycardia, hence IBW dosing
- May prolong the duration of regional blocks
IV lidocaine
- Anti-inflammatory, antihyperalgesic and opioid-sparing
- Dose by LBW given the risk of LA toxicity
- Account for any LA used in blocks or wound infiltration; consider delaying the infusion for 4-8h after a regional block
- Reduce or avoid in hepatic dysfunction
Ketamine
- The preferred parenteral non-opioid analgesic in severe obesity as it is opioid-sparing with minimal respiratory depression
- Infusions useful after painful surgery (spine, trauma, open abdominal) or where hyperalgesia is present
- Rescue analgesia in recovery: 2-5mg every 5-10min (maximum 20mg/h)
- Can be added to an opioid PCA
- Dose by IBW to avoid psychotomimetic effects
Gabapentinoids
- Associated with respiratory depression, particularly in the elderly, those with OSA and those receiving opioids
- Meta-analysis showed no clinically significant analgesic benefit, no prevention of chronic post-surgical pain and more adverse events
- Do not start perioperatively in severe obesity, especially with known or suspected SDB
- Continue in those already taking them, at a reduced dose if opioids are also being given, with extended monitoring
Other adjuncts
- Magnesium: NMDA and calcium channel blockade, also reduces PONV and shivering; evidence for analgesic benefit is low quality
- Dexamethasone: analgesic at doses >0.1mg/kg and recommended by bariatric ERAS guidelines; causes dose-dependent hyperglycaemia without clinically significant consequences, so is safe in diabetics
Regional & neuraxial techniques
- Technically more difficult, but ultrasound-guided block success remains high (~95%)
- Optimise patient positioning and operator ergonomics; a curvilinear probe and longer needles may be needed for deep targets e.g. TAP blocks
- Neuraxial: greater skin-to-epidural depth and impalpable landmarks; ultrasound reduces attempts, time and failure
- Intrathecal morphine
- Historically avoided in severe obesity/SDB due to concern for delayed respiratory depression
- At doses <0.3mg, risk of respiratory depression is lower than with IV opioids; 0.1mg in OSA did not increase pulmonary complications or apnoea severity
- Use where it is part of the standard protocol for that surgery, with respiratory monitoring for at least 24h
Opioids
- Acceptable with appropriate precautions; dose by LBW (AAGBI/SOBA)
- Do not increase dose or frequency unless there is chronic pain or opioid tolerance
- Use short-acting (fentanyl) or intermediate-acting (hydromorphone) opioids rather than long-acting or modified-release preparations
- IV PCA is reasonable, always alongside regular simple analgesia
- Avoid background opioid infusions, which are strongly associated with respiratory depression
Specific patient groups
- Elderly
- SDB increases with age and contributes to delirium risk
- Balance analgesia against sedation and polypharmacy; regional techniques are particularly useful
- Avoid gabapentinoids, tramadol, pethidine and high-dose or modified-release opioids
- Review home medications for withdrawal risk (e.g. benzodiazepines) and interactions
- NSAIDs at the lowest dose for the shortest duration
- Day-case
- Severe obesity alone does not predict prolonged recovery or readmission
- Patients with diagnosed and well-controlled OSA can safely undergo day-case surgery; consider whether the procedure will be very painful and whether it can be managed without opioids
- Use LA infiltration or blocks; deliberately prescribe regular paracetamol and NSAIDs; agree safe discharge opioid quantities with the surgeon
- Chronic pain and opioid tolerance
- Not immune to respiratory depression; chronic opioid use is associated with central apnoea in a dose-dependent manner
- Pre-operatively: screen for SDB, involve the pain team, calculate daily oral morphine equivalents, identify substance use disorders and counsel on expectations
- Keep in a monitored setting if opioid doses are increased or sedating drugs added; opioid rotation should be supervised by the acute pain service
- Previous bariatric surgery
- Oral drug absorption changes acutely and long-term
- Methadone levels rise after sleeve gastrectomy, buprenorphine levels fluctuate and oral morphine is absorbed faster after Roux-en-Y gastric bypass
- The health risk from obesity is not uniform, with increased risk of obesity-associated health conditions in Black African-Caribbean, Asian and elderly populations
BMI
- Obesity does not necessarily increase the risk of perioperative morbidity and mortality
- Class 3 obesity is associated with increased post-operative morbidity and mortality
- Conversely, class 1 & 2 patients often have a lower incidence of complications and mortality than normal weight patients, a finding across a range of surgeries
- Underweight patients carry the highest risk of mortality among the different categories of BMI
- This may be due to unrecognised differences between BMI groups rather than a beneficial effect from adipose tissue per se
Age
- Increasing age is associated with reduced functional reserve, and carries an increased risk of post-operative morbidity and mortality
- In obesity, this association is not as concrete
- In Class 3 obese patients undergoing PLIF, age >65yrs was independently associated with increased risk of post-operative complications
- Overall mortality was increased 3x in patients undergoing bariatric surgery aged >55yrs compared to those <55yrs
Distribution of fat
- Central (abdominal/visceral) obesity is defined as:
- Waist circumference >102cm (men) or >88cm (women)
- (Or >90cm and >80cm in Asian men and women)
- Adipose tissue distribution can be defined by CT and MRI
- However simple measurement of waist circumference can identify those with greater perioperative risk
- The distribution of fat predicts mortality more accurately than BMI
- Central obesity has greater associated risks of:
- Difficult airway/ventilation management
- Cardiovascular disease
- Metabolic syndrome
- Overall peri-operative risk
Presence of comorbidities
- The degree to which comorbidities increase peri-operative risk for obese patients is not clear
- OSA is associated with difficult airway management, unplanned re-intubation and post-operative cardiopulmonary complications
- Metabolic syndrome comprises a cluster of conditions and contributes majorly to perioperative morbidity and mortality, with increased risk of:
- Developing cardiovascular disease
- Developing T2DM
- Post-operative cardiac complications (2-3x)
- Post-operative pulmonary complications (1.5-2.5x)
- Stroke
- Sepsis
Functional capacity
- The ability to achieve >4 METs indicates a lower risk
- However, obese patients may not exert themselves to this degree and this does not alone define an unfit patient
- Sarcopenic obesity is characterised by reduced muscle mass and functionality in the presence of obesity
- There are trends towards adverse outcomes, particularly with age
- Varying diagnostic criteria result in the exact risk being unclear
- The presence of sarcopenic obesity is suggested by:
- Poor grip strength
- History of immobility
- Slow gait
Atelectasis in obesity
- Atelectasis occurs in up to 90% of patients under general anaesthesia and promotes other postoperative pulmonary complications (PPCs) such as pneumonia
- Risk is markedly greater in obesity due to raised pleural pressure, reduced alveolar pressure and impaired surfactant function
- After induction and neuromuscular blockade, abdominal and thoracic fat push the diaphragm cephalad; dependent regions develop negative transpulmonary pressure and collapse
- End-expiratory lung volume can fall by up to 50% in class 3 obesity, to levels comparable with severe ARDS
- Further worsened by pneumoperitoneum, Trendelenburg positioning and high FiO2 (absorption atelectasis); improved by a more upright position
- Collapse and reduced lung volume persist after extubation, causing post-operative desaturation
Role of PEEP and recruitment
- PEEP raises transpulmonary pressure to counteract the inward forces on the lung, maintaining end-expiratory lung volume and improving V/Q matching, compliance and oxygenation
- Due to hysteresis, the pressure needed to re-open collapsed alveoli is much higher than the pressure at which they close
- An alveolar recruitment manoeuvre (ARM) is therefore needed first; airway pressures of 40-50cmH2O may be required in obesity
- PEEP must then be kept above the closing pressure to prevent de-recruitment
- Adequate PEEP lowers driving pressure, a surrogate of lung strain that is closely associated with outcome
- Pleural pressure is not uniform: it is highest in dependent lung, so PEEP high enough to open dorsal lung may overdistend ventral lung
| Advantages of PEEP in obesity | Disadvantages of PEEP in obesity |
| Reduced atelectasis and maintained lung volume | Overdistension of non-dependent lung if excessive |
| Improved compliance and lower driving pressure | ↑ PVR and RV afterload if overdistended |
| Improved V/Q matching and oxygenation | ↓ Venous return, especially with hypovolaemia or cardiovascular disease |
| Reduced hypoxic pulmonary vasoconstriction → ↓ RV afterload | Hypotension and bradycardia with accompanying ARMs |
| Prevents airway closure and cyclical opening | Physiological benefits lost within hours of extubation |
Evidence
- The PROBESE trial (JAMA, 2019) compared PEEP 12cmH2O with ARMs vs. PEEP 4cmH2O in obese surgical patients
- High PEEP improved respiratory mechanics and gas exchange
- No reduction in PPCs, and more intra-operative hypotension in the high PEEP/ARM group
- 12cmH2O may have been too low; studies personalising PEEP in class 3 obesity typically find optimal levels of 15-25cmH2O, rising with BMI
- In practice, over 75% of obese patients receive PEEP ≤5cmH2O
- Personalised PEEP improves intra-operative physiology, but improvement in patient-centred outcomes has not yet been shown
Cardiovascular effects of PEEP
- The heart and great vessels are affected by pleural pressure, whereas the pulmonary circulation is affected by transpulmonary pressure
- In obesity, the already high pleural pressure (25-30cmH2O under GA) buffers the circulation from the effects of PEEP; reduced venous compliance and increased stressed volume help maintain venous return
- Studies of personalised PEEP in obesity show preserved cardiac output and no increase in vasopressor requirement, even at PEEP >20cmH2O
- Recruitment manoeuvres, rather than PEEP itself, appear to be the main cause of hypotension and bradycardia; take particular care with hypovolaemia, shock or cardiovascular disease
- PEEP reduces LV transmural pressure and therefore LV afterload
- At emergence, atelectasis, increased work of breathing and upper airway obstruction can generate large negative intrathoracic pressures, increasing LV afterload and venous return; this risks pulmonary oedema and extubation failure
A practical approach to personalised PEEP
- Start lung protective ventilation: VT 6-8ml/kg predicted body weight, PEEP 10cmH2O
- Suspect significant atelectasis if:
- Driving pressure >14cmH2O
- Progressively falling static compliance
- Hypoxaemia or rising FiO2 requirement
- Recruitment manoeuvre: confirm haemodynamic stability, then deliver 3-6 breaths at a plateau pressure of 40-50cmH2O
- Decremental PEEP trial (volume-controlled ventilation):
- Start at 20-25cmH2O, adjusted for BMI and surgical conditions
- Reduce in 2cmH2O steps every 10 breaths whilst monitoring static compliance
- Select the lowest PEEP that gives the highest compliance
- Reassess as conditions change (insufflation, positioning); if haemodynamic compromise occurs, avoid further ARMs and consider lowering PEEP
Perioperative management of the obese patient
History and examination
- Document weight and BMI
- Elucidate functional status
- Identify important factors such as:
- Whether fat distribution is central or peripheral
- The presence of metabolic syndrome
- SpO2 <95% on room air
- Presence of other comorbidities that require investigation and optimisation
Investigations
- These will be guided by the individual's comorbidities and the surgery planned
- Respiratory
- Resting SpO2 on air
- History: dyspnoea, wheeze
- Screening e.g. STOP-BANG
- FBC to check for polycythaemia
- ABG to check for hypercapnoea and/or raised bicarbonate
- Spirometry
- Cardiovascular
- Resting HR, NIBP
- History: exertional chest pain, palpitations, overt features of heart failure, syncope
- 12-lead ECG
- Exercise capacity ± CPET
- TTE
- Cardiology input
- Metabolic
- Serum glucose
- HbA1c
- LFTs
- Actively seek components of metabolic syndrome
- Diabetes/endocrine input
Risk assessment
- Risk prediction can be facilitated with the Obesity Surgery Mortality Risk Score (OS-MRS); it is only validated in bariatric surgery but may be used in non-bariatric surgery
- The score can be used to plan the need for postoperative care; a score of 4-5 indicates a high-risk patient and should prompt consideration of post-operative HDU admission
| Risk Factor | Score |
| BMI >50kg/m2 | 1 |
| Male | 1 |
| Hypertension | 1 |
| Age >45yrs | 1 |
| Any risk factor for PE: OSA/OHS Previous VTE Right heart failure Pulmonary hypertension IVC filter inserted pre-operatively |
Max 1 |
Considerations for day surgery
- Obesity in-and-of itself is not a contraindication to day surgery, and severe obesity alone does not predict prolonged recovery or readmission
- Other than a requirement for long-acting post-operative opioids, there are no significant anaesthetic or surgical factors which will otherwise contraindicate the obese patient having day surgery
- Diagnosed and well-controlled OSA is not a barrier; consider whether the procedure will be very painful and whether it can be managed with non-opioid techniques
- Several patient factors may make day surgery inappropriate, such as:
- Poor functional capacity
- Unstable respiratory or cardiac disease
- Metabolic syndrome
- OS-MRS of 4 or 5
- Previous VTE
Planning analgesia
- Identify comorbidities which affect analgesia (SDB, hepatic/renal dysfunction, chronic pain, chronic opioid use, psychosocial factors) and other predictors of poorly controlled pain
- Refer those at risk of persistent post-surgical pain to specialist pain services
- Chronic pain patients: involve the pain team, calculate daily oral morphine equivalents and screen for SDB early
- The 'evaluate, educate, engage, empower' approach
- Evaluate: comorbidities and pain risk as above
- Educate: set realistic expectations and reduce anxiety and catastrophising
- Engage: increase activity and prehabilitation before surgery
- Empower: patients record their own baseline function (e.g. 6-minute walk test, peak expiratory flow) and work towards a 'return to baseline' after surgery
Optimisation & planning
- Consider CPAP/NIV for patients with OSA/OHS; positive airway pressure therapy in OSA is associated with a 28% reduction in post-operative respiratory complications and 56% reduction in unplanned ICU admission
- Medical management of cardiovascular and metabolic comorbidities
- Weight loss where possible
- Senior anaesthetist and senior surgeon on the list
- Allow extra list time for both anaesthetic and surgical components
- Plan for HDU/ICU post-operatively if appropriate; diabetes, respiratory disease and open abdominal surgery are associated with higher risk of unanticipated ICU admission
General equipment
- Suitable gowns and theatre-wear of appropriate size
- Appropriate transfer equipment should be available:
- Patient should maintain their own mobility as much as possible
- Equipment such as chairs, trolleys and beds should be safe to use at patient’s weight
- May require use of hover mattresses or similar devices
- Adequate staff members present to facilitate safe transfer
- Oxford HELP pillow or ramping device
- Large IPCs or TEDS (10x increased risk DVT)
- Sufficient staff to move the patient
- Once on the operating table, require:
- Extra-wide extensions or arm gutters
- Gel pads to protect pressure points as prolonged pressure can cause ischaemia and rhabdomyolysis (classically gluteal ischaemia)
Anaesthetic equipment
- Large NIBP cuff; may need to use forearm for measurement
- Do not routinely require intra-arterial BP monitoring
- Predict difficult intubation therefore VL and associated difficult airway kit
- Long spinal/epidural and regional needles, and a curvilinear ultrasound probe, if RA planned
- Ultrasound machine in case of difficult vascular access
- Ventilator capable of delivering suitable driving pressure and PEEP
- Neuromuscular monitoring as higher potential for incomplete reversal of NMBA
Induction & airway
- Obesity is associated with a higher risk of developing airway problems under anaesthesia, with NAP4 demonstrating:
- 2x rate of adverse events (esp. with SAD)
- Higher failure of rescue techniques
- Routine airway assessment should be performed, with particular emphasis on identifying:
- Mallampati III (predicts difficult facemask ventilation and intubation)
- Neck circumference >42cm (one of the best predictors of difficult intubation)
- BMI >50 kg/m2 (independent predictor of both difficult intubation and facemask ventilation)
- The presence of a beard
- Symptoms of gastro-oesophageal reflux disease
- Induction
- In theatre to mitigate unnecessary transfer risk and allow greater space and access to assistance
- Induce in ramped position as maintains FRC, reduces dyspnoea and facilitates BVM/laryngoscopy
- Airway choices
- Likely to require intubation and therefore need appropriate equipment to facilitate this, including video laryngoscopy and adjuncts
- A SAD may be appropriate; a 2nd generation device should be used and should definitely be used with caution if BMI >40kg/m2
- An airway plan should be vocalised and DAS guidelines followed
- Routine fibreoptic intubation is not recommended
- FONA may be more difficult if required and have higher rate of failure/complications; may be appropriate in high risk cases to identify the depth of the cricothyroid membrane, vascular tissue, and mark relevant landmarks to improve the chance of success
- Obesity is associated with an increased incidence of known risk factors for aspiration
- However, obesity alone does not increase risk of reflux and pulmonary aspiration
- In the absence of other risk factors, routine performance of RSI is not required
- There is a higher risk of hypercapnoea and hypoxia, as increased body tissue mass and work of breathing leads to greater oxygen consumption and CO2 production
- FRC is reduced to closing capacity and causes atelectasis and hypoxia, due to:
- Excess adipose tissue, which reduces lung compliance and raises pleural pressure
- Lying supine
- General anaesthesia and neuromuscular blockade
- Effect of pneumoperitoneum
Maintenance of anaesthesia
- NAP5 revealed an increased incidence of awareness in obese patients shortly after induction of anaesthesia, due to rapid redistribution of anaesthetic agents
- In order to reduce occurrence, anaesthetists should ensure:
- Adequate dosing of IV agent
- Prompt delivery of maintenance anaesthetic agent
- Further bolus(es) of anaesthetic agent before airway manipulation or protracted airway manoeuvres
- Using processed EEG-based depth of anaesthesia monitoring to reduce risk of awareness
- TIVA with propofol offers a number of potential advantages over volatile anaesthesia for the obese patient:
- Reduced incidence of laryngospasm
- Maintained anaesthesia during protracted airway manipulation
- Rapid offset with ‘clear-headed’ emergence
- Reliable clearance of hypnotic agents
- Reduced PONV
- Using volatile agents with a rapid offset of action (low blood:gas partition coefficient) e.g. desflurane/sevoflurane should limit adipose absorption and reduce risk of re-sedation at emergence
Ventilation
- Obesity is an independent risk factor for developing postoperative pulmonary complications
- Current recommendations for ventilation include:
- Lung protective volumes (6-8ml/kg predicted body weight)
- Plateau pressure <30cmH2O outside of recruitment manoeuvres
- Initial PEEP of around 10cmH2O, then individualised; class 3 obesity often requires >15cmH2O
- Recruitment manoeuvres and a decremental PEEP trial where atelectasis is suspected (see Ventilation and PEEP under general anaesthesia)
- Re-titrate PEEP with changes in positioning and pneumoperitoneum, e.g. Trendelenburg position in lower abdominal surgery with laparoscopy
Analgesia
- Opioid-sparing multimodal approach: regular paracetamol and NSAIDs, regional or neuraxial techniques and surgical LA infiltration where possible
- Consider dexmedetomidine, ketamine or lidocaine infusions, dosed by the appropriate scalar (see Analgesia in severe obesity)
- Single-dose dexamethasone as part of PONV prophylaxis also provides analgesia
Reversal of NMBA and emergence
- The hazards of airway/respiratory problems during emergence are greater in the obese population
- To mitigate for this ensure:
- Ventilate with FiO2 1.0 until FEO2 >0.9
- Sit upright or at least ramped
- Full reversal of NMBA with appropriate doses of sugammadex or neostigmine
- Only extubate once fully awake
Effect of previous bariatric surgery
- Patients may have undergone previous bariatric surgery
- This may influence conduct of anaesthesia
- Adjustable gastric banding
- High risk of aspiration even with prolonged fasting times
- Antacid premedication + RSI technique
- Avoid routine NGT insertion as risk of band displacement or perforation
- Do not deflate band without discussing with a bariatric surgeon
- Sleeve gastrectomy
- Routinely intubate even if no other risk factors for aspiration
- High risk of gastric reflux even in the absence of symptoms
- Malabsorptive surgery
- Small bowel shortening can affect oral bioavailability of drugs, in particular post-operative analgesia
- Avoid prolonged NSAID use after any bariatric surgery due to the risk of anastomotic ulceration
- Recover in upright position
- Consider HDU care for those with existing hypoventilatory issues, need for NIV or other need for closer monitoring
- Continue home CPAP/NIV; the intra-operative benefits of PEEP are lost within hours of extubation as atelectasis recurs
- Multi-modal opioid-sparing analgesic strategy
- Use of intra-operative IV agents as part of a multi-modal approach reduces opioid usage, PONV, POPC, PACU length of stay and hospital LOS (BJA, 2024)
- Regular paracetamol and NSAIDs unless contraindicated
- Small IV ketamine boluses as rescue analgesia, or low-dose infusions for hyperalgesia or escalating opioid requirements
- Aim to avoid opioids where possible to limit respiratory depression
- If using, use short-acting opioids e.g. fentanyl; PCA without a background infusion
- Do not start gabapentinoids
- Monitoring
- If IV opioids are required, continuous saturations monitoring should be in situ
- Monitor for at least 24h after intrathecal morphine
- The first 24h after long-acting opioids carries the highest risk of respiratory depression
- Naloxone readily available
- Multi-modal anti-emesis as standard
- Robust venous thromboprophylaxis
- Early mobilisation
- Chemical prophylaxis based on total body weight dosing
- After discharge
- Early follow-up to ensure pain is well-controlled and safely managed
- Discharge opioid quantities agreed with the surgical team
- Patients track their recovery against their own pre-operative baseline